M. McGowan

发表

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia

P. Duell, P. Moriarty, M. McGowan, 2019, Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.

There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients

M. McGowan, 2004, Circulation.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.

M. McGowan, 2013, Journal of clinical lipidology.

Nutritional supplements and serum lipids: Does anything work?

M. McGowan, S. Proulx, 2009, Current atherosclerosis reports.

Familial hypercholesterolaemia: too many lost opportunities

M. Cuchel, M. McGowan, 2021, The Lancet.

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD

D. Rader, D. Staszak, W. Howard, 2021, American journal of preventive cardiology.

A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model

A. Khera, W. Weintraub, Katherine A. Wilemon, 2021, American journal of preventive cardiology.

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Jennifer G. Robinson, S. Daniels, D. Rader, 2011, Journal of clinical lipidology.

Liver histology during Mipomersen therapy for severe hypercholesterolemia.

R. Odze, R. Santos, E. Stroes, 2014, Journal of clinical lipidology.

Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Matthew K. Ito, P. Moriarty, M. McGowan, 2011, Journal of clinical lipidology.

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis

Laney K. Jones, Ilene G. Ladd, Nephi A. Walton, 2021, Circulation. Genomic and precision medicine.

Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study

Laney K. Jones, Ilene G. Ladd, S. Gidding, 2021, Journal of personalized medicine.

The effects of mipomersen, a secondgeneration antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia

P. Moriarty, M. McGowan, J. Backes, 2014 .

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

D. Gaudet, D. Tribble, E. Stein, 2012, Circulation.

Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease

M. McGowan, 2011, Current treatment options in cardiovascular medicine.

Intervention in hypercholesterolemic college students: a pilot study.

A. Duggan, M. McGowan, A. Joffe, 1994, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

J. Tardif, S. Chasan-Taber, G. Wagener, 2012, PloS one.

Jennifer G. Robinson, S. Daniels, D. Rader, 2011, Journal of clinical lipidology.

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

D. Waters, C. Shear, D. Herrington, 2004, The American journal of cardiology.

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

J. Kastelein, Joann D Flaim, B. Baker, 2014, Journal of the American Heart Association.

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2023, Journal of the American Heart Association.

Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach

Laney K. Jones, R. Brownson, A. Goldberg, 2023, Frontiers in Health Services.

DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: A WORK IN PROGRESS

J. Knowles, D. Rader, D. Macdougall, 2023, American Journal of Preventive Cardiology.

Social support of inner-city fathers and mothers.

A. Duggan, M. McGowan, K. Boehm, 1995, Archives of pediatrics & adolescent medicine.

Abstract 16531: Decreased Cardiovascular Events in Familial Hypercholesterolemic Patients Treated With Mipomersen, an Antisense Inhibitor of Apolipoprotein B Translation

J. Kastelein, R. Santos, B. Baker, 2014 .

Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia

A. Sturm, A. Rahm, Emilie Simmons, 2023, BMC Health Services Research.

APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA

J. Tardif, S. Chasan-Taber, G. Wagener, 2011 .

Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use

G. Wan, L. Christopher‐Stine, M. Reed, 2020, Journal of managed care & specialty pharmacy.